The biomarker data presented at AD/PD 2026 from the Phase III APOLLOE4 trial showed that in the MCI subgroup, ...

Can a spinal fluid test diagnose Parkinson’s? Researchers have identified DOPA decarboxylase as a key biomarker that separates Parkinson’s and Lewy body dementia from other forms of cognitive decline.

We reveal health patterns of daily life through patient-centric digital biomarkers – accelerating personalised healthcare and ...

An international consortium has achieved a major breakthrough in the diagnosis of neurological diseases. In a recent ...

Current schizophrenia medications treat symptoms such as hallucinations and delusions, but do little for cognitive symptoms ...

A study has found a new biomarker of schizophrenia, which could also serve as a drug target for treating cognitive symptoms such as disorganised thinking or executive function. Schizophrenia is a ...

The field of Alzheimer’s disease (AD) research has evolved significantly, shifting from a sole reliance on clinical diagnosis to an integrated approach ...

Microscopic sensors that are as thin as a strand of hair but capable of taking multiple measurements simultaneously could ...

In this segment, Dr. Gregory Vidal discusses when biomarker testing is performed during the treatment journey for ER-positive ...

This article explores how multiomics integration, imaging, and bioinformatics are advancing biomarker discovery, revealing ...

Is it possible to draw conclusions about an adult's physical condition on the basis of their age? The answer is: "It depends.

Professor David Kerr warns against 'treating the marker' in CRC. Should rising ctDNA trigger chemo without radiologic proof?